The European Medicines Agency said it’s no longer in crisis mode as pandemic-related activities taper off, and the agency is more coordinated than ever before and ready for new drug shortages that come this winter.
Emer Cooke, executive director of the EMA, on Monday told the European Parliament’s Committee on Environment, Public Health and Food Safety that there’s been a notable increase in the agency’s business activities in 2023, including the fact that biosimilar applications have more than doubled when compared to last year. Several members of Parliament questioned Cooke about different developments, including pharma-related legislation proposed in the spring that will likely include new regulatory reforms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.